Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sirna-cox-2
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- In Vitro (experimental), Delivery Routes (e.g., Local Injection, Nanoparticle, Viral, Or Bacterial Vectors) Have Been Explored In Research Settings[3]
01
Overview
sirna-cox-2 refers to a small interfering RNA (siRNA) molecule specifically designed to silence the expression of the cyclooxygenase-2 (COX-2) gene. COX-2 is an inducible enzyme involved in the biosynthesis of prostaglandins, playing a key role in inflammation, tumorigenesis, and several pathological processes. By targeting the mRNA of COX-2, sirna-cox-2 mediates its degradation via the RNA interference pathway, resulting in reduced COX-2 protein production. This targeted gene-silencing approach is considered highly selective compared to nonsteroidal anti-inflammatory drugs (NSAIDs), which may have off-target effects. Preclinical experiments have demonstrated the utility of sirna-cox-2 in cancer models by reducing tumor growth, inflammation, and cell proliferation, as well as in studies of hypertrophic scarring and related pathologies[1][3][4].
- Other names
- coX-2 siRNAcoX2 siRNAcoX 2 siRNAsiCOX-2siCOX2siCOX 2
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on sirna-cox-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sirna-cox-2.